Cybin Turning Psychedelics-to-Therapeutics(TM) Vision Into Reality

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Cybin CYBN CYBN, a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. “The company is working on turning its Psychedelics to Therapeutics(TM) vision into reality by engineering drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders,” reads a recent article, which contains excerpts from a USA Today report that touts psychedelics as the next big thing in mental health treatment. “The [USA Today] article noted that Dr. Matthew W. Johnson, a professor of psychiatry and behavioral sciences at Johns Hopkins and acting director of the Johns Hopkins Center of Psychedelics and Consciousness Research, has seen a gradual increase in interest around psychedelics since he began focusing on them in 2004, but he said interest now is increasing dramatically; he thinks that interest will only increase moving forward.” This dramatic increase bodes well for Cybin, one of the leaders in the psychedelic space.

To view the full article, visit https://ibn.fm/jnM41

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Image sourced from Pixabay

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.